评估药物吸收气球与临时分叉病变的支架:短期结果和未来方向
Muhammad Ziyad1, Syed Tahir Shah1, Muhammad Abdur Rauf2
1Cardiology, Kuwait Teaching Hospital, Peshawar, PAK.
Cureus
|March 6, 2025
概括
药物释放气球 (DEB) 和支架在临时分叉病变中显示出类似的短期安全性和有效性. DEBs提供了一个更简单的程序,可能有利于患有复杂冠状动脉解剖的患者.
科学领域:
- 干预心脏病学 干预心脏病学
- 心血管疾病 心血管疾病
背景情况:
- 两叉病变在干预心脏病学中带来了复杂的挑战,增加了复原,阻塞和血栓事件的风险.
- 将药物释放气球 (DEB) 与临时支架进行比较,对于优化这些复杂病变的治疗策略至关重要.
研究的目的:
- 评估和比较DEBs的短期临床结果,手术成功和安全性与临时分叉病变中的临时支架相比.
- 评估关键不良事件,包括主要不良心脏事件 (MACE),静脉缩,目标病变再血管化 (TLR),心肌梗塞 (MI),支架血栓形成和死亡率.
主要方法:
- 一项前性队列研究涉及50名患有分叉病变的患者,随机分为两组:25人接受DEB治疗,25人接受临时支架.
- 干预后一个月和三个月进行了后续评估.
- 所有患者都接受了双重抗血小板治疗 (DAPT) 和其他必要的药物.
主要成果:
- DEB和支架都显示出可比的短期疗效和安全性,MACE (8%对12%,p=0.58),复原 (4%对8%) 和TLR (4%对8%) 的比例相似.
- 两组中心脏病发病率都很低 (4%),没有报告的支架血栓形成或死亡.
- 在不需要额外干预的情况下,DEB治疗取得了成功,而支架则增加了程序的复杂性.
结论:
- 在临时分叉病变的短期有效性和安全性方面,DEB和支架是可比的,DEB提供了程序简单性.
- DEBs代表了对选择的双叉病变的可行的替代方案,可能避免与支架相关的复杂性.
- 需要进行更长的随访时间的大型研究来证实这些发现并指导临床实践.
更多相关视频
06:55Fabrication of Small Caliber Stent-grafts Using Electrospinning and Balloon Expandable Bare Metal Stents
Published on: October 26, 2016
8.8K
13:48Reduction of Radiation Exposure during Endovascular Treatment of Peripheral Arterial Disease Combining Fiber Optic RealShape Technology and Intravascular Ultrasound
Published on: April 21, 2023
1.4K
相关概念视频
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:20Measurement of Bioavailability: Pharmacodynamic Methods
Pharmacodynamic methods provide insights into a drug's effects on physiological processes over time and play a crucial role in understanding bioavailability and therapeutic efficacy. These methods can be broadly classified into acute pharmacological and therapeutic response approaches, each with distinct mechanisms and applications.The acute pharmacological response method directly correlates a drug's physiological effects, such as ECG or pupil diameter changes, to its time course in the body.
01:05Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:09Bioequivalence of Drugs: Drugs with Multiple Indications
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each indication due to...
01:30Modified-Release Drug Delivery Systems: Bioavailability
Modified-release (MR) dosage forms are designed to extend drug release over time, thereby maintaining stable plasma concentrations and reducing dosing frequency. However, their bioavailability is typically below 100% due to incomplete drug release and presystemic metabolism, and limitations in drug permeability across the gastrointestinal epithelium, all of which can restrict the fraction of the drug reaching systemic circulation. Consequently, studying the in vivo bioavailability of MR...